# A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

> **NCT05671315** · NA · UNKNOWN · sponsor: **Qing XIe** · enrollment: 267 (estimated)

## Conditions studied

- Chronic Hepatitis B
- Intermediate to High Risk of HCC

## Interventions

- **DRUG:** Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
- **DRUG:** Nucleos(t)ide analogue

## Key facts

- **NCT ID:** NCT05671315
- **Lead sponsor:** Qing XIe
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-03
- **Primary completion:** 2023-08
- **Final completion:** 2026-04
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05671315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05671315, "A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05671315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*